Tirzepatide vs Semaglutide for Men's Fat Loss in 2026

Tirzepatide produces meaningfully greater fat loss than semaglutide in head-to-head and comparative data — roughly 20% body weight reduction versus 15% at peak doses — and that gap matters for men carrying significant visceral adiposity. The choice between them still depends on cardiovascular history, cost, and what you're willing to tolerate side-effect-wise.

What the Trials Actually Show

The clearest summary of the efficacy gap comes from the pivotal phase 3 programs. In SURMOUNT-1, published in NEJM, adults on tirzepatide 15 mg (sold as Zepbound) lost a mean 20.9% of body weight at 72 weeks versus placebo's 3.1% [4]. In STEP-1, also published in NEJM, semaglutide 2.4 mg (Wegovy) delivered 14.9% mean weight loss at 68 weeks [6]. Meta-analyses comparing the two directly place tirzepatide's advantage at roughly 4–7 percentage points of total body weight, a difference that's clinically real, not statistical noise [2][5].

For men specifically, sex-stratified analyses of the STEP trials reveal a consistent pattern: men lose somewhat less relative weight than women on semaglutide — treatment differences in STEP-1 run approximately −14% for women versus −8% for men versus placebo [1]. Comparable male-specific breakdowns from the SURMOUNT program haven't been published in granular detail, but the absolute kilograms lost at higher baseline male body weights remain substantial. Men should expect a slower early response and shouldn't declare the drug a failure at 90 days.

If you're comparing your options across providers, the weight management treatment hub lays out how telehealth prescribers currently approach drug selection and dosing protocols.

The Cardiovascular and OSA Angles Matter More for Men

Men present to weight-loss programs with higher baseline cardiovascular risk than women at equivalent BMI, which makes the SELECT trial — a cardiovascular outcomes study of semaglutide published in NEJM in 2023 — directly relevant. SELECT demonstrated that Wegovy reduced major adverse cardiovascular events (MACE) by 20% in adults with established CVD and overweight or obesity, earning semaglutide a cardiovascular risk-reduction label extension. For a man with a prior MI who also needs to lose 30 kg, semaglutide isn't just a weight drug — it's a cardioprotective therapy with a fat-loss side effect.

Tirzepatide's cardiovascular outcomes data are still maturing, though trials are underway. What Zepbound does have is an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity — a condition that disproportionately affects men and is often undertreated. Men who are CPAP-resistant or who want to address both visceral fat and OSA simultaneously have a pharmacologic argument for tirzepatide that goes beyond the scale number. See our deeper look at tirzepatide vs semaglutide for cardiovascular health for the outcomes data side-by-side.

For men without established CVD who simply want maximum fat loss and are otherwise healthy, tirzepatide wins on efficacy. For men with prior cardiovascular events, semaglutide's SELECT-backed label gives it a legitimate edge — or at minimum, a stronger evidence base for the conversation with a prescriber.

Cost, Access, and the Compounded Drug Question

Brand-name Wegovy and Zepbound carry list prices above $1,000/month without insurance. In practice, most men accessing these drugs through telehealth platforms are using compounded semaglutide or compounded tirzepatide from 503A/503B pharmacies, often at $200–$400/month. The FDA's shortage-based compounding window for semaglutide has narrowed considerably in 2026, though compounded tirzepatide remains more accessible. That access picture shifts the practical calculus: tirzepatide's efficacy advantage becomes even more compelling when it's also the more affordable compounded option in your geography.

If you're evaluating telehealth providers that prescribe either drug, Shed offers both semaglutide and tirzepatide protocols with physician oversight and iterative dose titration. For a broader comparison of platforms, online weight-loss providers lists current options with pricing transparency ratings. Also worth reading before you commit: compounded tirzepatide vs Zepbound — what's actually different in 2026.

One non-negotiable note on safety: both drugs carry the FDA's REMS-adjacent labeling warning about theoretical thyroid C-cell tumor risk based on rodent data. Neither is appropriate for men with personal or family history of medullary thyroid carcinoma or MEN2. That's a screening question every prescriber should ask upfront [8].

Frequently asked questions

Which drug causes more fat loss in men — semaglutide or tirzepatide?

Tirzepatide produces greater fat loss than semaglutide in men, based on both individual trial data and comparative meta-analyses [2][5]. SURMOUNT-1 showed tirzepatide 15 mg achieving roughly 20.9% mean body weight reduction versus STEP-1's 14.9% for semaglutide 2.4 mg at comparable timepoints. Men should also know that both drugs show a slightly attenuated relative percentage loss compared to women, so setting expectations around the 8–12% range at 68 weeks on semaglutide — and somewhat higher on tirzepatide — is more realistic than citing headline trial averages.

Should men with heart disease choose semaglutide over tirzepatide?

Men with established cardiovascular

How much does tirzepatide cost compared to semaglutide for men using telehealth platforms?

Compounded versions of both drugs through telehealth platforms typically cost $200–$400 per month, compared to brand-name list prices above $1,000 per month for both Wegovy and Zepbound without insurance. Men accessing these medications through 503A/503B pharmacies can achieve significant savings over brand-name pricing. However, the FDA's shortage-based compounding window for semaglutide has been narrowing, which may affect future availability and pricing of the compounded option.